Environmental Exposure Detection Technologies and/or Decontamination Treatments for Military Working Dogs - SBIR DHA26BZ01-NV003

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop decontamination treatments for military working dogs that have been exposed to toxic industrial chemicals and materials through the performance of their duties.

Description:

This topic is in support of the DoD Working Dog Strategic Research Plan concerning mitigation, countermeasures and treatments for toxin/toxic exposures1. In modern military operations, military working dogs (MWDs) are at risk of exposure by many different types of hazardous materials. These include toxic industrial chemicals (TICs) and materials (TIMs) such as hydrocarbons, polychlorinated biphenyls, glycols, hazardous metals, gases (hydrogen cyanide, hydrogen sulfide, freon, carbon monoxide, etc.), acids and alkali substances. Techniques for the decontamination of hazardous material exposures to the surface of the MWD are well defined2,3,4. Although there are useful treatment options for external decontamination, there are few treatment options for toxic exposures that have been absorbed into the body of the MWD.

The objective of this topic is to develop new treatments for MWDs against hazardous materials that have been absorbed into the body either through the skin or mucous membranes, by inhalation, or ingestion. Current systemic treatments employed to care for MWDs include supportive antibiotic therapy for sulfur mustard, atropine injections for nerve agents, and Narcan for narcotics, but there are limited treatment options available for TIC/TIM exposures4,5,6. Systemic treatments for the MWD should be able to be performed by veterinarians and their support personnel (trained animal care specialists (68T) in Role 1 and/or veterinary medical and surgical teams (VMST) in Role 2). Potential MWD systemic treatments could include but are not limited to kits containing indicators or detectors of TIC/TIM exposure with easily identifiable injectable treatments for the identified contaminant (indicator/detector) and/or hemoperfusion systems and filters that can be used to remove contaminants from the blood (systemic). This research topic does not support the use of canines for testing purposes. Any animal testing would require use of a suitable animal model that would approximate the response of a canine.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Development of Wearable Device for Detecting Biomarkers and Treating Viral and Bacterial Infections - SBIR DHA26BZ01-NV004

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a non-invasive wearable device that can discretely detect biomarkers for and provide initial broad-spectrum treatment for pan-viral and pan-bacterial infections. If fielded for military use, it may require additional security measures.

Description:

The DHA Strategic Research Plan (SRP): Environmental Exposures (June 2024) lists two capability requirements under the “Assess” and “Treat” capability areas that align with this proposal: Environmental Detection and Health Risk Assessments under Assess and Environmental Exposures Treatment under Treat. In addition, the DHA SRP: Military Infectious Diseases (May 2024) lists three capability requirements under the “Prevent”, “Treat”, and “Enable” capability areas that align with this proposal: Prevention of Military Relevant Endemic and Emerging Infectious Diseases under Prevent, Treatment of Military Relevant Endemic and Emerging Infectious Diseases under Treat, and Core Competencies under Enable.

The Department of the Air Force (DAF) is looking for an advanced, non-invasive (does not break the skin or physically enter the body) wearable device (i.e., flash/continuous glucose style monitoring) capable of qualitatively detecting all-viral and all-bacterial infections using discrete biomarkers for such infections: TRAIL, MxA, CD46, IP-10, PTX3, or other non-blood based biomarkers (saliva, sweat, etc.) for viral infections and CRP, PCT, IL-6, IL-8, CD35, CD55, CD64, pro-ADM, or other non-blood based biomarkers (saliva, sweat, etc.) for bacterial infections. The end goal is a wearable device that discretely detects viral and bacterial infections and renders initial, broad-spectrum anti-viral or anti-bacterial treatment(s) at austere operational environments where no immediate medical countermeasures and no other detection capabilities are available until casualties are evacuated to locations with more robust medical resources for additional and specific differentiation and treatment. At a higher echelon of care, medical personnel must be able to receive data from the device to find out what category of threats (viral or bacterial) has triggered a biomarker detection and what corresponding treatments have been rendered to the affected force before providing more advanced care.

By continuously monitoring validated biomarkers, this device will empower warfighters to detect and respond to biological threats early, enhancing their survivability and operational effectiveness in high-threat theaters and mitigating risks to mission and force. This Air Force Medical Command initiative improves force health protection and ensures mission success. Dual-use functionality of this technology will focus on civilian healthcare systems.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Detection and Treatment of Traumatic Brain Injury in Military Working Dogs - SBIR DHA26BZ01-NV002

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Evaluate previously developed traumatic brain injury (TBI) detection and treatments methods that can be repurposed for use in military working dogs (MWDs) after suffering from battlefield injuries.

Description:

This topic is in support of the DoD Working Dog Strategic Research Plan concerning mitigation, strategies, and treatments for the detection and treatment of TBI.1 Due to the high-risk nature of MWD operations, TBI is a common injury. TBI in the MWD carries an extremely high mortality rate with a prehospital mortality of over 40% for severe TBI cases. It is estimated that 25-40% of all MWD trauma cases are accompanied by TBI, but there is limited data concerning the short- and long-term effects of TBI on the performance and health of the MWD. Current clinical detection methods for TBI in the MWD are by the observation of altered mentation (coma, stupor, depression, lethargy, inappropriate behavior or responses) of the MWD and by use of the modified veterinary Glasgow coma scale or with physical evidence of head trauma (e.g., lacerations, abrasions, bruising, swelling, pain, bleeding from the nose or ears). Current treatment guidelines for TBI in MWDs are largely based on treatment recommendations for humans and are primarily supportive measures to maintain blood pressure, oxygen levels, proper ventilation, and body temperature to mitigate secondary injuries2,3,4. There have been many TBI detection methods and treatment strategies developed for humans that have shown promising results in rodent and large animal models5. The objective of this SBIR is to review research that was performed in rodents, canines, or other large animal models that could be repurposed for the detection and treatment of TBI specifically in MWDs. This research topic does not support the use of canines for testing purposes. Any animal testing would require use of suitable animal model that would approximate the response of a canine.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Military Working Dog Whole Blood Product or Substitute - SBIR DHA26BZ01-NV001

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $250,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a whole blood product or substitute to aid in hemorrhage control for Military Working Dogs (MWD) after battlefield injury that can be used near the point of injury (POI) and throughout the continuum of care to reduce morbidity and mortality.

Description:

This topic is in support of the DoD Working Dog Strategic Research Plan concerning solutions for bleeding control and coagulopathy support.1 The Military Working Dog (MWD) provides a unique and important service to the warfighter. MWDs serve as sentries, perform tracking and patrol, and are used for the detection of explosives. These activities come with a high risk of injury. Uncontrolled hemorrhage following traumatic injury accounts for over 45% of all MWD battlefield deaths2. The current standard of care for hemorrhage in the MWD is to provide immediate fluid therapy through the delivery of crystalloid fluids as the first-line treatment, which is then followed by a synthetic colloid or hypertonic saline. These treatments also require the administration of supplemental oxygen to maintain appropriate oxygen levels and for the survival of the MWD3. To improve their survival rates, the development of a shelf stable canine whole blood product or substitute is a critical priority

The goal of this topic is to develop a stable canine whole blood product and/or substitute (i.e. hemoglobin or polymer oxygen carriers), intended for canine use at both POI and throughout the continuum of care. The product should have a shelf-life of greater than 3 years and be thermal stable (-9℃ to 60℃) to ensure accessibility in operational environments. The product must primarily replicate the oxygen carrier characteristics of whole blood and demonstrate the ability to be used safely and effectively to treat blood loss following traumatic injury. This research topic does not support the use of canines for testing purposes. Any animal testing would require use of suitable animal models that would approximate the response of a canine.

Blood products derived from canine donors must be negative for canine red blood cell antigens DEA 1.1 and DEA 1.2. Donor animals must also be tested for blood borne diseases including canine brucellosis, hemobartonellosis, Borrelia burgdorferi (Lyme disease), Dirofilaria immitis (heartworm disease), Ehrlichia canis, Rocky Mountain spotted fever, Coccidioides immitis, Babesia canis, Babesia gibsoni, Mycoplasma haemocanis and plasma levels of von Willebrand factor. All donor animals must be current on immunizations for canine distemper, hepatitis, parainfluenza, leptospirosis, parvovirus, Bordatella, coronavirus and rabies virus as applicable.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II) - SBIR DHA26BZ01-DV005

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $1.3 Million

Deadline to Apply:

Est. April 29th, 2026.

Objective:

This topic is intended for technology proven ready to move directly into Phase II and accepts Direct to Phase II proposals only. The proposed research will focus on identifying compounds with broad-spectrum activity against clinically relevant fungal pathogens while minimizing toxicity to humans. The primary objective is to identify a small molecule with fungicidal properties that are safe for human use, with FDA clearance.

Description:

Fungal infections represent a growing global health challenge, particularly among immuno-compromised individuals. Invasive fungal infections caused by pathogens such as Candida species, Aspergillus species, Fusarium species, and Mucor species are associated with high morbidity and mortality rates. Fungal infections are associated with 130k hospitalizations, 13 million outpatient visits, and result in a financial burden of $19 billion on the civilian health care sector. Fungal wound infections in particular are also growing challenge for the military. Despite the availability of antifungal agents, current treatments are often limited by toxicity, drug resistance, and narrow-spectrum activity. The emergence of multidrug-resistant fungal strains, such as Candida auris, has further exacerbated the need for novel antifungal therapies. Small molecules with antifungal properties offer a promising avenue for addressing these challenges. Their ability to target specific fungal pathways, combined with the potential for oral bioavailability and low manufacturing costs, makes them ideal candidates for therapeutic development. However, significant scientific and technical hurdles remain with the discovery and optimization of small molecules that are both effective against fungal pathogens and safe for human use. Qualified proposals should identify small molecules with antifungal properties from an existing library. These small molecules should be active against all of the following fungi: Fusarium species, Aspergillus species, Candida auris, or Mucorales species. Qualified molecules will have antifungal activity at nanomolar concentrations. Further, these small molecules must have a cytotoxicity profile similar, or better than Amphotericin B.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below:

Low-Cost, Phased Array Antennas for Collaborative Jamming in sUAS Swarms - SBIR Topic DAF26TZ01-NV004

Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.

Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.

Funding Amount:

Est. $140,000

Deadline to Apply:

Est. April 29th, 2026.

Objective:

Develop a low-cost, phased array antenna system and associated signal processing techniques for collaborative jamming applications using small to medium-sized sUAS swarms (3-7 units).

Description:

This topic addresses the need for affordable and scalable jamming capabilities leveraging sUAS swarms. Instead of focusing on individual, high-power jammers, this STTR seeks to develop a collaborative jamming approach using multiple sUAS equipped with low-cost phased array antennas.

The key innovation is the development of a low-cost phased array antenna system that can be precisely controlled to focus jamming energy on specific targets. By coordinating the signals from multiple sUAS in a swarm, the effective jamming power can be significantly increased. The focus on low to medium-sized swarms (3-7 units) allows for manageable coordination and control strategies.

This approach offers several advantages over traditional jamming techniques, including:

 Increased jamming effectiveness through beamforming.

 Improved resilience through redundancy.

 Reduced risk of detection and counter-attack.

 Lower cost compared to high-power jamming systems.

Who will win?

If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.

Who is eligible to apply?

Any company that meets the following criteria:

• For-profit company

• U.S.-owned and controlled.

• 500 or fewer employees (including affiliates)

How Can BW&CO Help?

1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.

2) Proposal strategy and review.

3) Administrative & compliance support.

Request to talk with a member of our team by completing the form below: